Skip to content

Study · Not a test of the peptide alone · 2025

1 result

Short- and long-term glycemic effects of pasireotide in patients with acromegaly: a comprehensive case study with review of literature.

Taki Y, Kono T, Matsuda T, Kozu R, Fujimoto M, Sakuma I, Hashimoto N, Horiguchi K, Higuchi Y, Tanaka T

Endocrine journal22 Jan 2025Cited by 2 (Europe PMC)

PMID39842795 (opens in a new tab)PMCIDPMC11997266 (opens in a new tab)DOI10.1507/endocrj.ej24-0548 (opens in a new tab)PepBankPUB-39842795
Read at sourcePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

  1. 01HumanNot a test of Semaglutide aloneCase report or seriesEfficacy outcome

    In a patient with acromegaly on long-term pasireotide, the glycaemic response was controlled by different GLP-1 receptor agonists, including semaglutide.

    In plain wordsIn one patient with acromegaly, high blood sugar from pasireotide was controlled by several GLP-1 drugs, semaglutide among them.

    Peptide
    Semaglutide
    Outcome
    DecreaseControl of pasireotide-induced hyperglycaemia
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    In the second case, long-term PAS therapy resulted in a dose-dependent glycemic response that was controlled by different GLP-1 receptor agonists (GLP-1RAs), including semaglutide.
    1 context sentence
    Summary · context
    Herein, we present two cases of acromegaly treated with PAS and highlight its short- and long-term effects on glucose metabolism.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.